All In Biotech

Drug Trial Radar · NCT07566052

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

356

Planned (sponsor's estimate)

Start

Aug 19, 2026

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If the cancer gets worse, the next main treatment is usually a medicine called docetaxel. This treatment doesn't stop most people's cancer from getting worse for very long. Other treatments are needed to improve outcomes in people with NSCLC. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with NSCLC have a faulty KRAS gene in their tumor. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation. Setidegrasib (ASP3082) is thought to remove some of the abnormal proteins made from the faulty KRAS gene. Before setidegrasib can become available as a treatment, studies need to be done. This study is for people with NSCLC with a faulty KRAS gene in their tumor. In this study, some people will be given setidegrasib and some people will be given docetaxel. The main aims are to learn how long people who are given setidegrasib live with cancer without it getting worse, compared to people who are given docetaxel, and if they live for longer. Other aims are to check tumor response, symptoms, how the body processes setidegrasib, and its safety, compared with docetaxel. The main aims of study are to learn how long people who are given setidegrasib live with cancer without it getting worse, compared to people who are given docetaxel and if people who are given setidegrasib live for longer compared to people who are given docetaxel. People in this study will be adults with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) with the G12D mutation in their KRAS gene. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. They have had no more than 2 previous treatments for their cancer. The key reasons people cannot take part are if they have different faulty genes in their tumor which can be targeted with other treatments, have symptomatic or untreated cancers that have spread from the lung into the brain or nervous system, their cancer has spread to the thin tissue that covers the brain and spinal cord (leptomeningeal disease), or they have recently had other active cancers that required treatment. In this study, people will either receive setidegrasib or docetaxel. Whether people receive setidegrasib or docetaxel is decided by chance, not by the study doctor. Both study treatments are given slowly through a tube into a vein (infusion). People will continue to receive study treatment until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatment, they or the doctor decides the person should stop receiving study treatment, or sadly, they pass away. Some people on docetaxel may be able to switch to setidegrasib during the study if their cancer becomes worse. There will be safety checks at each visit, and the doctors will continue to check for medical problems and people's wellbeing throughout the study. People will continue to have scans of their tumor every 6 weeks for the first year, then every 9 weeks until their cancer becomes worse. After people's cancer becomes worse, clinic staff will telephone people every 12 weeks to check on their cancer.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • SetidegrasibDrug

    Intravenous infusion

  • DocetaxelDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR)Time frame: Up to 2.3 years
  2. Overall Survival (OS)Time frame: Up to 4.2 years

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • Oncura Health d.b.a.Los Angeles Cancer Network

    Glendale, California · Recruiting

  • UCLA Health - Santa Monica Cancer Care

    Los Angeles, California · Recruiting

  • UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Baptist Health - Boca Raton Regional Hospital

    Boca Raton, Florida · Recruiting

  • Astera Cancer Care

    Edison, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Texas Oncology-Longview Cancer Center

    Longview, Texas · Recruiting

  • Virginia Cancer Specialists

    Arlington, Virginia · Recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Huangpu District, China · Recruiting

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Shangcheng District, China · Recruiting

  • The First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Sichuan Cancer Hospital & Institute

    Chengdu, Sichuan, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Yuexiu District, China · Recruiting

  • Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan · Recruiting

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Hiroshima, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Hyogo Cancer Center

    Akashi, Hyōgo, Japan · Recruiting

  • Kanagawa Prefectural Hospital - Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan · Recruiting

  • Japanese Foundation for Cancer research

    Tokyo, Koto-ku, Japan · Recruiting

  • Miyagi Cancer Center

    Natori-shi, Miyagi, Japan · Recruiting

  • Niigata Cancer Center Hospital

    Niigata, Niigata, Japan · Recruiting

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan · Recruiting

  • Kindai University Hospital

    Sakai, Osaka, Japan · Recruiting

  • Shizuoka Cancer Center

    Nagaizumi-cho, Sunto-gun, Shizuoka, Japan · Recruiting

  • Tokyo Metropolitan Hospital

    Bunkyo-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.